CO2021001290A2 - Compuestos peptídicos y usos terapéuticos de los mismos - Google Patents
Compuestos peptídicos y usos terapéuticos de los mismosInfo
- Publication number
- CO2021001290A2 CO2021001290A2 CONC2021/0001290A CO2021001290A CO2021001290A2 CO 2021001290 A2 CO2021001290 A2 CO 2021001290A2 CO 2021001290 A CO2021001290 A CO 2021001290A CO 2021001290 A2 CO2021001290 A2 CO 2021001290A2
- Authority
- CO
- Colombia
- Prior art keywords
- therapeutic uses
- peptide compounds
- dexamethasone
- mouse
- reducing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL26055518 | 2018-07-11 | ||
| PCT/IL2019/050774 WO2020012478A2 (en) | 2018-07-11 | 2019-07-10 | Peptide compounds and therapeutic uses of same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021001290A2 true CO2021001290A2 (es) | 2021-02-26 |
Family
ID=69141375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0001290A CO2021001290A2 (es) | 2018-07-11 | 2021-02-05 | Compuestos peptídicos y usos terapéuticos de los mismos |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11912790B2 (https=) |
| EP (2) | EP3820882B1 (https=) |
| JP (2) | JP7395517B2 (https=) |
| KR (1) | KR102880543B1 (https=) |
| CN (1) | CN112351989B (https=) |
| AU (2) | AU2019300567B2 (https=) |
| BR (1) | BR112020024748A2 (https=) |
| CA (1) | CA3100961A1 (https=) |
| CO (1) | CO2021001290A2 (https=) |
| EA (1) | EA202190249A1 (https=) |
| ES (1) | ES3026158T3 (https=) |
| HR (1) | HRP20250746T1 (https=) |
| HU (1) | HUE072141T2 (https=) |
| IL (2) | IL280101B2 (https=) |
| MX (1) | MX2021000264A (https=) |
| PL (1) | PL3820882T3 (https=) |
| RS (1) | RS66946B1 (https=) |
| SG (1) | SG11202012773QA (https=) |
| WO (1) | WO2020012478A2 (https=) |
| ZA (1) | ZA202100587B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL280101B2 (en) | 2018-07-11 | 2025-05-01 | Immunity Pharma Ltd | Peptide compounds and their therapeutic uses |
| IL272074B2 (en) * | 2020-01-15 | 2024-12-01 | Immunity Pharma Ltd | Peptide compounds and methods of treating diseases using same |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| JPS4843906B1 (https=) * | 1970-08-11 | 1973-12-21 | ||
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| WO1997044447A2 (en) * | 1996-05-03 | 1997-11-27 | President And Fellows Of Harvard College | Transcriptional activation system, activators, and uses therefor |
| US6861256B2 (en) * | 1997-05-15 | 2005-03-01 | The General Hospital Corporation | Therapeutic and diagnostic tools for impaired glucose tolerance conditions |
| GB9711148D0 (en) * | 1997-05-31 | 1997-07-23 | Peptide Therapeutics Ltd | Human MAFA |
| EP0928968A1 (en) | 1998-01-12 | 1999-07-14 | Universität Basel | Screening method for apoptosis and necrosis |
| CA2443314C (en) | 2001-04-03 | 2006-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of imaging cell death in vivo |
| US20040204340A1 (en) | 2003-04-11 | 2004-10-14 | Guilford Pharmaceuticals, Inc. | Polyprolyl inhibitors of cyclophilin |
| AU2005276117C1 (en) * | 2004-08-23 | 2013-04-18 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Peptide inhibitors for mediating stress responses |
| KR20070100832A (ko) * | 2005-02-01 | 2007-10-11 | 아테뉴온, 엘엘씨 | 항혈관신생 ｐｈｓｃｎ 펩티드를 함유하는 조성물 |
| US7704953B2 (en) | 2006-02-17 | 2010-04-27 | Mdrna, Inc. | Phage displayed cell binding peptides |
| BR112012006005A2 (pt) * | 2009-09-17 | 2017-09-19 | Univ Ramot | "peptídeos no tratamento de transtorno associados ao estresse oxidativo" |
| WO2011126882A2 (en) * | 2010-03-30 | 2011-10-13 | American Type Culture Collection | Therapeutic peptides and their derivatives and therapeutic uses thereof |
| EP2593595B1 (en) * | 2010-07-16 | 2020-03-11 | Avantgen, Inc. | Novel peptides and uses thereof |
| PL2655612T3 (pl) * | 2010-12-23 | 2017-12-29 | Shell Internationale Research Maatschappij B.V. | Czynniki uszkadzające geny produkujące pochodne tłuszczowego acylo-coa |
| CA2836503C (en) | 2011-05-23 | 2020-09-22 | Yeda Research And Development Co. Ltd. | Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same |
| US20140271666A1 (en) * | 2013-03-14 | 2014-09-18 | Immune Pharmaceuticals Ltd. | Use of anti-eotaxin antibodies for treating inflammatory bowel disease |
| CN104045703B (zh) * | 2013-03-15 | 2021-04-06 | 深圳君圣泰生物技术有限公司 | 一种多肽、多肽衍生物、多肽的可药用盐及药物组合物 |
| US8802633B1 (en) | 2013-03-18 | 2014-08-12 | Board Of Regents, The University Of Texas System | Autophagy-inducing peptide analogs |
| EP3169343B1 (en) * | 2014-07-15 | 2020-03-25 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Isolated polypeptides of cd44 and uses thereof |
| US9453061B2 (en) * | 2014-08-06 | 2016-09-27 | Brown University | Method and compositions for treatment of calcineurin-related diseases |
| BR112017022845A2 (pt) | 2015-04-23 | 2018-07-17 | Nantomics, Llc | neoepítopos de câncer |
| WO2017011338A1 (en) | 2015-07-10 | 2017-01-19 | President And Fellows Of Harvard College | Sortase-mediated coupling of immunogenic polysaccharide-protein conjugates and their use |
| IL280101B2 (en) | 2018-07-11 | 2025-05-01 | Immunity Pharma Ltd | Peptide compounds and their therapeutic uses |
| IL272074B2 (en) | 2020-01-15 | 2024-12-01 | Immunity Pharma Ltd | Peptide compounds and methods of treating diseases using same |
-
2019
- 2019-07-10 IL IL280101A patent/IL280101B2/en unknown
- 2019-07-10 SG SG11202012773QA patent/SG11202012773QA/en unknown
- 2019-07-10 RS RS20250622A patent/RS66946B1/sr unknown
- 2019-07-10 IL IL317252A patent/IL317252A/en unknown
- 2019-07-10 MX MX2021000264A patent/MX2021000264A/es unknown
- 2019-07-10 AU AU2019300567A patent/AU2019300567B2/en active Active
- 2019-07-10 EP EP19752749.2A patent/EP3820882B1/en active Active
- 2019-07-10 EA EA202190249A patent/EA202190249A1/ru unknown
- 2019-07-10 BR BR112020024748-0A patent/BR112020024748A2/pt unknown
- 2019-07-10 KR KR1020217004105A patent/KR102880543B1/ko active Active
- 2019-07-10 CN CN201980041027.6A patent/CN112351989B/zh active Active
- 2019-07-10 US US17/254,867 patent/US11912790B2/en active Active
- 2019-07-10 HR HRP20250746TT patent/HRP20250746T1/hr unknown
- 2019-07-10 WO PCT/IL2019/050774 patent/WO2020012478A2/en not_active Ceased
- 2019-07-10 CA CA3100961A patent/CA3100961A1/en active Pending
- 2019-07-10 PL PL19752749.2T patent/PL3820882T3/pl unknown
- 2019-07-10 EP EP25167540.1A patent/EP4566617A3/en active Pending
- 2019-07-10 JP JP2020573032A patent/JP7395517B2/ja active Active
- 2019-07-10 ES ES19752749T patent/ES3026158T3/es active Active
- 2019-07-10 HU HUE19752749A patent/HUE072141T2/hu unknown
-
2021
- 2021-01-27 ZA ZA2021/00587A patent/ZA202100587B/en unknown
- 2021-02-05 CO CONC2021/0001290A patent/CO2021001290A2/es unknown
-
2023
- 2023-11-29 JP JP2023201767A patent/JP7682248B2/ja active Active
-
2024
- 2024-02-26 US US18/586,715 patent/US20240190919A1/en active Pending
- 2024-12-16 AU AU2024278477A patent/AU2024278477A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021001912A2 (es) | Composiciones anti-cd112r y métodos | |
| CO2020016619A2 (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso | |
| CY1121953T1 (el) | Κυτταροδιεισδυτικα πεπτιδια και μεθοδοι παρασκευης και χρησης αυτων | |
| UY37456A (es) | Inmunoglobulinas y sus usos | |
| CO2020001983A2 (es) | Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anticd39 | |
| CL2018002687A1 (es) | Proteínas de unión y métodos de uso de las mismas | |
| CO2022002622A2 (es) | Anticuerpos anti-cd73 y composiciones | |
| BR112016030965A2 (pt) | Composições de veículo-anticorpo e métodos de fabricação e uso das mesmas | |
| MX2018007288A (es) | Anticuerpos neutralizantes para el virus de inmunodeficiencia humana. | |
| ECSP17074645A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
| MA52542A (fr) | Thérapie cellulaire adoptive | |
| MX2020004801A (es) | Polipeptidos de fusion biespecificos y sus metodos de uso. | |
| CY1124761T1 (el) | Ρυθμιστες της δραστικοτητας του συμπληρωματος | |
| CO2019009080A2 (es) | Péptidos y métodos para el tratamiento de diabetes | |
| CL2020000101A1 (es) | Compuestos de cetonas bicíclicas y métodos de uso de los mismos. | |
| MX2021002301A (es) | Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos. | |
| MX2021002225A (es) | Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion. | |
| CO2021001290A2 (es) | Compuestos peptídicos y usos terapéuticos de los mismos | |
| BR112021013206A2 (pt) | Bibliotecas de peptídeos e respectivos métodos de uso | |
| CL2022001138A1 (es) | Anticuerpos tmem219 y usos terapéuticos de los mismos | |
| CO2017010692A2 (es) | Construcciones de calicheamicina y sus métodos de uso | |
| CO2017010621A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| DK3561056T5 (da) | Peptid til behandling af aldersrelateret makuladegeneration | |
| CO2019013315A2 (es) | Proteínas recombinantes robo2, composiciones, métodos y usos de las mismas | |
| ECSP22019177A (es) | Proteínas de fusión nkg2d y sus usos |